Case Report

Unilateral minimal ovarian cancer with peritoneal implant and an intraepithelial carcinoma in the contralateral fallopian tube

Hiroyuki Terada1, Ken-ichi Honda1∗, Tomoko Nakagawa1, Aki Takase2, Yasushi Kurihara1, Tetsuji Ando1, Masashige Tendo3, Takeshi Hori3, Keiko Miyamoto4, Mayumi Inaba5, Masahiko Ohsawa6

1Department of Obstetrics and Gynecology, Kashiwara Municipal Hospital, Hozenji, Kashiwara, Osaka, Japan
2Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine, Asahimachi, Abenoku, Osaka, Japan
3Department of Surgery, Kashiwara Municipal Hospital, Hozenji, Kashiwara, Osaka, Japan
4Department of Pathology, Kashiwara Municipal Hospital, Hozenji, Kashiwara, Osaka, Japan
5Department of Pathology, Kansai Medical University Medical Center, Fumizonocho, Moriguchi, Osaka, Japan
6Department of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Asahimachi, Abeno-ku, Osaka, Japan

Received: 04 February 2017
Revised: 24 February 2017
Accepted: 06 March 2017

∗Correspondence:
Dr. Ken-ichi Honda,
E-mail: kenhonda@med.osaka-cu.ac.jp

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Here we present postoperative pathology of an 82-year-old woman who presented with massive ascites, and an implant-like adenocarcinoma on her infrapelveal peritoneum, which revealed a minimal (<5mm) serous adenocarcinoma on her left ovary and an intraepithelial carcinoma on inner surface of her right Fallopian tube. The left ovary serous adenocarcinoma may have originated as an intraepithelial carcinoma on contralateral Fallopian tube.

Keywords: Contralateral fallopian tube, Intraepithelial carcinoma, Ovarian serous adenocarcinoma

INTRODUCTION

Primary extraovarian peritoneal carcinoma reportedly accounts for ~10% of diagnoses of ovarian cancer.1 Recently, we treated an 82-year-old woman whose ovary seemed normal during surgery despite massive ascites and two implant-like lesions on her pelvic peritoneal surface; however, postoperative pathologic examination revealed a minimal serous carcinoma (<5 mm) on her left ovary and an intraepithelial carcinoma in her right fallopian tube.

We consider the carcinoma cells had likely originated in the fallopian tube and transferred to her contralateral ovary, developed invasive properties, and became implanted on the retroperitoneum.

CASE REPORT

A 82-year-old woman came to our clinic because of abdominal distension. Ultrasound examination showed massive ascites, but CT revealed no mass in the abdominal organs except for a uterine myoma with calcification (Figure 1). Her serum CA125 level was 408 U/mL, and adenocarcinoma cells were detected by ascites cytology. We performed exploratory laparotomy, with bilateral adnexectomy and supravaginal hysterectomy.
We also resected two implant-like protrusions on her left retroperitoneum (Figure 2).

Although, no tumor was seen macroscopically on the bilateral adnexa (Figure 3).

Microscopic examination confirmed a serous adenocarcinoma with invasion on her left ovary (Figure 4A) and two serous adenocarcinoma implants on her left retroperitoneum (Figure 4B), and an intraepithelial carcinoma on inner surface of her right fallopian tube, near fimbriae (Figure 5).

According to guideline of Japan Society of Gynecologic Oncology for stage IIb ovarian cancer with serum CA25 serum level of 226 U/mL, we recommended postoperative chemotherapy with paclitaxel and carboplatin to the patient. However, as the patient preferred not to undergo chemotherapy with strong side effects (e.g. hairloss), we scheduled carboplatin monotherapy.
After the third course of chemotherapy, her serum CA125 level was 9 U/mL and the patient strongly hoped to finish the chemotherapy. Four months later, abdominal distension reappeared, and serum CA125 level was again elevated to 185 U/mL. We diagnosed the cancer to have recurred within 6 months, and began third-line chemotherapy with liposomal doxorubicin. After 2 cycles of chemotherapy, her ascites disappeared and serum CA125 level was decreased to 89 U/mL.

DISCUSSION

At the consensus meeting of the International Federation of Gynecology and Obstetrics (FIGO) in 2012, localized primary peritoneal cancer was classified as stage II.2 In the present case, the primary ovarian cancer that was overlooked at macroscopic examination was found to be <5mm by pathologic examination, with the two peritoneal implants localized in pelvic cavity; the ovarian cancer was also stage II b.

As a small ovarian cancer may be overlooked, bilateral salpingo-oophorectomy is recommended in a patient with peritoneal cancer. In the absence of an obvious lesion, pathologic examination of ovary and fallopian tube specimens is important for accurate staging and evaluation.

Based on molecular genetics and morphologic studies, epithelial ovarian cancer is classified into two categories, type I, which include cancers with well-identified ovarian precursors, including low-grade serous carcinomas; and type II, which includes cancers with less-obvious precursors, including high-grade serous cancers.3,4 In up to 60% of cases with sporadic high-grade serous carcinoma of ovary, serous tubal intraepithelial carcinomas were found.5 Extensive evaluation protocols of fallopian tubes have shown the fimbriated end to be the most common site of serous tubal intraepithelial carcinoma. Their reports proposed that many serous ovarian cancers originate from tubal intraepithelial carcinoma, and the schema shows the carcinoma cells moving from the fimbriae to the same side ovary.6 Our case suggests that the carcinoma cells can move from a fimbria to the contralateral ovary.

CONCLUSION

Serous ovarian cancer could originate from an intraepithelial carcinoma of contralateral fallopian tube.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES
